Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03462342 · ClinicalTrials.gov registry record · Phase 2
Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer
A Phase 2 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 2
- Development phase
- 123
- Enrollment target
NCT03462342: Completed Phase 2 study, sponsored by University of Pennsylvania.
NCT03462342 is a Phase 2 study that has completed, run by University of Pennsylvania. The registered enrollment target is 123 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03462342, a Phase 2 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 123 participants
- Enrollment target
Study Summary
Investigational agent, AZD6738 will be given in combination with Olaparib to women with recurrent ovarian cancer (platinum-sensitive or platinum-resistant). This study will determine if using Olaparib in combination with AZD6738 is safe and tolerable and also determine the objective response rate and progression free survival of combination of AZD6738 and Olaparib in women with recurrent ovarian cancer in distinct platinum-sensitive and platinum-resistant cohorts.
Interventions
- DRUG Olaparib Pill
- DRUG AZD6738
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2018-03-09 |
| Est. Completion | 2025-07-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03462342
The ClinicalTrials.gov registry entry for NCT03462342 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 123 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Olaparib Pill is the first listed.
NCT03462342 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03462342 about?
NCT03462342 is a clinical study titled "Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer". Investigational agent, AZD6738 will be given in combination with Olaparib to women with recurrent ovarian cancer (platinum-sensitive or platinum-resistant). This study will determine if using Olaparib in combination with AZD6738 is safe and tolerable and also determine the objective response rate a...
What is the current status of trial NCT03462342?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 123 participants. The study started on 2018-03-09. Estimated completion is 2025-07-21.
What interventions are being tested in trial NCT03462342?
The interventions under investigation include: Olaparib Pill (DRUG), AZD6738 (DRUG).
Who is sponsoring clinical trial NCT03462342?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.